Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
ICS + LABA combination inhaler

Budesonide with formoterol

Brand names: Symbicort, DuoResp Spiromax, Fobumix

This is a combination inhaler of inhaled budesonide (corticosteroid) with formoterol (long-acting beta-2 agonist), used for maintenance treatment of asthma and COPD and, in asthma, as a single inhaler for both maintenance and relief.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Budesonide suppresses airway inflammation through glucocorticoid receptors while formoterol provides fast-onset, long-acting bronchodilation via beta-2 adrenoceptors.

Prescribing in practice

  • Most important: a long-acting beta-2 agonist must never be used alone in asthma, so this fixed inhaler should be the sole LABA source and the corticosteroid component taken reliably.
  • Where licensed for maintenance-and-reliever therapy, ensure the patient understands using the same inhaler for symptom relief and does not duplicate LABA therapy.
  • Prescribe by brand and confirm device-specific inhaler technique.

Monitoring

Monitor asthma or COPD control, inhaler technique, oral candidiasis, and childhood growth on long-term use.

Counselling the patient

  • Rinse the mouth after each dose to reduce oral thrush and hoarseness.
  • Use it exactly as prescribed, including any maintenance-and-reliever instructions.

Evidence & guidelines

ICS/LABA combinations including budesonide with formoterol are established maintenance and MART therapy in NICE and GINA guidance.

Reference: NICE NG80; BTS/SIGN; GINA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways